Related content

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

By Prete Salvatore   Montella Liliana   Caraglia Michele   Maiorino Luigi   Cennamo Gregorio   Montesarchio Vincenzo   Piai Guido   Febbraro Antonio   Tarantino Luciano   Capasso Elena   Palmieri Giovannella   Guarrasi Rosario   Bianco Maddalena   Mamone Rosanna   Savastano Clementina   Pisano Agata   Vincenzi Bruno   Sabia Antonietta   D’Agostino Alberto   Faiola Vincenzo   Addeo Raffaele  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 837-844

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma

By                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1099-1102

Science Publishers

Access to resources Recommend Favorite

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

By                          

Experimental and Therapeutic Medicine, Vol. 2, Iss. 3, 2011-01 ,pp. : 433-441

Spandidos Publications

Access to resources Recommend Favorite

Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium

By Hainsworth John D.   Waterhouse David M.   Penley William C.   Shipley Dianna L.   Thompson Dana S.   Webb Charles D.   Anthony Greco F.  

Cancer Investigation, Vol. 31, Iss. 5, 2013-06 ,pp. : 323-329

Informa Healthcare

Access to resources Recommend Favorite

Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma

By Moroni Marco   Zanlorenzi Laura  

Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1231-1237

Future Medicine

Access to resources Recommend Favorite